Clinical Trial Update: Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating allogeneic CD30.CAR-EBVSTs in relapsed or refractory CD30-positive lymphomas, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Extranodal Natural Killer T-cell Lymphoma Nasal Type

Drugs mentioned

• CD30.CAR EBVSTs (CD30-targeted chimeric antigen receptor T cells with EBV-stimulated T cells and constitutive IL7R (C7R) modification)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma | Phase 1 | Status: RECRUITING